semaglutide adolescent obesity trial 2022 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 - Kushner - 2020 - GLP-1 Agonists in Adolescent Obesity:

Research Papers

There is a randomized controlled phase 2 study with the objective to explore the use of TZP as a treatment for MAFLD, providing strong evidence [NCT04166773]

This was reproduced in a companion experiment with semaglutide and MAR709, another GLP-1/GIP dual agonist

Some cause fewer side effects

A gastroenterologist explains this well: "The same sense of fullness, or 'early satiety,' that prevents overeating can also slow the gut down" [9]

Theres no other class of drugs where people want to violate HIPAA as much as they do the GLP-1 because its like, Oh, I gotta know, Trotter said, referring to the federal law restricting the release of medical information